TNF and metabolic dysfunction-associated steatotic liver disease: In patients with psoriasis and NAFLD, the use of etanercept (an anti-TNF-α proteic drug) seemed to prevent hepatic fibrosis, reduce transaminases levels, and improve IR (measured by the homeostasis model assessment (HOMA) index), supporting the hypothesis that these two diseases are pathophysiologically connected through glucose homeostasis alteration and cytokine dysregulation [157].